Publication Name	World Journal of Clinical Oncology
Manuscript ID	85125
Country	United States

Received	2023-04-12 20:31
Peer-Review Started	2023-04-12 20:33
To Make the First Decision
Return for Revision	2023-06-21 09:42
Revised	2023-07-05 22:17
Second Decision	2023-07-27 02:42
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-07-27 08:00
Articles in Press	2023-07-27 08:00
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-08-17 01:39
Publish the Manuscript Online	2023-08-22 02:04

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail
Manuscript Source	Unsolicited Manuscript
All Author List	Ahmed Elhariri, Ahmed Alhaj, Daniel Ahn, Mohamad Bassam Sonbol, Tanios Bekaii-Saab, Christina Wu, Michael Scott Rutenberg, John Stauffer, Jason Starr, Umair Majeed, Jeremy Jones, Mitesh Borad and Hani Babiker
Funding Agency and Grant Number
Corresponding Author	Ahmed Elhariri, MD, Research Fellow, Division of Hematology-Oncology, Department of Medicine, Mayo Clinic Florida, Mayo Clinic Cancer Center, 4500 San Pablo Rd, Jacksonville, FL 32224, United States. ahmed.elhariri@bcm.edu
Key Words	Kirsten rat sarcoma virus; Targeted therapy; Pancreatic cancer; Drug resistance; Next generation sequencing; Clustered regularly interspaced short palindromic repeats
Core Tip	Kirsten rat sarcoma virus (KRAS) mutation is the hallmark of pancreatic cancer (PC) and an important therapeutic target. Approaches to target this oncogene has been challenging. We herein discuss the role of KRAS in development of PC, efforts made to target this pathway, and ongoing clinical trials.
Publish Date	2023-08-22 02:04
Citation	Elhariri A, Alhaj A, Ahn D, Sonbol MB, Bekaii-Saab T, Wu C, Rutenberg MS, Stauffer J, Starr J, Majeed U, Jones J, Borad M, Babiker H. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. World J Clin Oncol 2023; 14(8): 285-296
URL	https://www.wjgnet.com/2218-4333/full/v14/i8/285.htm
DOI	https://dx.doi.org/10.5306/wjco.v14.i8.285

Full Article (PDF)	WJCO-14-285-with-cover.pdf
Full Article (Word)	WJCO-14-285.docx
Manuscript File	85125_Auto_Edited-JLW.docx
Answering Reviewers	85125-Answering reviewers.pdf
Audio Core Tip	85125-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	85125-Conflict-of-interest statement.pdf
Copyright License Agreement	85125-Copyright license agreement.pdf
Peer-review Report	85125-Peer-review(s).pdf
Scientific Misconduct Check	85125-Bing-Lin C-2.png
Scientific Editor Work List	85125-Scientific editor work list.pdf